Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Localized and systemic scleroderma.

A Hawk¹, J C English

¹Department of Dermatology, University of Virginia School of Medicine, Charlottesville 22908-0718, USA.

Seminars in Cutaneous Medicine and Surgery

|April 20, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Inpatient teledermatology improves diagnostic accuracy and management of erythroderma in hospitalized patients.

Clinical and experimental dermatology·2021

Same author

EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk.

Oncogene·2013

Same author

Evidence-based treatment and prevention of external genital warts in female pediatric and adolescent patients.

Journal of pediatric and adolescent gynecology·2012

Same author

Misplaced pulmonary arteries in an adult patient with pulmonary hypertension.

The British journal of radiology·2010

Same author

A pleural mass with pulmonary infiltrates.

Thorax·2007

Same author

A diagnostic algorithm for male genital oedema.

Journal of the European Academy of Dermatology and Venereology : JEADV·2007

Same journal

Systemic therapy for advanced cutaneous squamous cell carcinoma.

Seminars in cutaneous medicine and surgery·2019

Same journal

Atypical Fibroxanthoma.

Seminars in cutaneous medicine and surgery·2019

Same journal

Introduction, High-Risk Skin Cancer.

Seminars in cutaneous medicine and surgery·2019

Same journal

Emerging technologies for health information in dermatology: opportunities and drawbacks of web-based searches, social media, mobile applications, and direct-to-consumer genetic testing in patient care.

Seminars in cutaneous medicine and surgery·2019

Same journal

MoleMapper: an application for crowdsourcing mole images to advance melanoma early-detection research.

Seminars in cutaneous medicine and surgery·2019

Same journal

Digital imaging applications and informatics in dermatology.

Seminars in cutaneous medicine and surgery·2019

See all related articles

Scleroderma, a fibrotic condition, includes localized and systemic forms. Systemic scleroderma presents as limited or diffuse disease, each with distinct clinical features, antibody profiles, and organ involvement.

Area of Science:

Rheumatology
Dermatology
Immunology

Background:

Scleroderma encompasses localized and systemic sclerosis, characterized by fibrosis.
Localized scleroderma involves cutaneous fibrosis (morphea, linear).
Systemic scleroderma (sclerosis) presents as limited or diffuse disease.

Purpose of the Study:

To discuss the classification, epidemiology, pathogenesis, clinical manifestations, treatment, and prognosis of scleroderma.
To differentiate between localized and systemic scleroderma subtypes.
To outline diagnostic criteria and management strategies for scleroderma.

Main Methods:

Review of existing literature on scleroderma classification and clinical presentation.
Analysis of epidemiological data and pathogenetic mechanisms.

Related Experiment Videos

Synthesis of current treatment guidelines and prognostic factors.

Main Results:

Scleroderma classification includes localized (morphea, linear) and systemic (limited, diffuse) forms.
Limited systemic sclerosis involves distal symptoms, specific organ fibrosis, and anticentromere antibodies.
Diffuse systemic scleroderma features proximal symptoms, multi-organ fibrosis, and specific autoantibodies (antitopoisomerase, anti-RNAP III).

Conclusions:

Accurate classification of scleroderma subtypes is crucial for understanding disease progression and treatment.
Early diagnosis and targeted therapies based on specific scleroderma manifestations improve patient outcomes.
Further research into pathogenesis and novel treatments is warranted for both localized and systemic scleroderma.